Ozempic in India: What it does and how it fits into a growing health crisis
From regulating appetite to improving blood sugar control, GLP-1 drugs like Ozempic are emerging as powerful metabolic tools at a time when India urgently needs better solutions
Analysis-Alzheimer’s Drug Hunt Learns From Cancer Fight’s Multi-Target Playbook
By Deena BeasleyDec 12 (Reuters) – Alzheimer’s trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore…
GLP-1s Cut Dementia Risk vs DPP-4 in Dialysis Patients
Patients with diabetes undergoing hemodialysis who initiate GLP-1 agonists have an 18% lower risk for incident dementia than those who initiate DPP-4 inhibitors. Medscape Medical News
JCM, Vol. 14, Pages 8792: Functional and Aesthetic Periorbital, Ocular Adnexal and Ocular Surface Changes Linked to GLP-1 Receptor Agonists
JCM, Vol. 14, Pages 8792: Functional and Aesthetic Periorbital, Ocular Adnexal and Ocular Surface Changes Linked to GLP-1 Receptor Agonists Journal of Clinical Medicine doi: 10.3390/jcm14248792 Authors: Dimitrios Kapantais Panagiotis Tsoutsanis Background/Objectives: Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have revolutionised obesity and type 2 diabetes management through effective weight loss and […]
Nature Metabolism: Alcohol addiction and liver damage are driven by endogenous fructose metabolism
A new paper in Nature Metabolism offered huge validation to the emerging theory that “fructose is the primary driver of metabolic syndrome”. The Paper: Identification of a common ketohexokinase-dependent link driving alcohol intake and alcohol-associated liver disease in mice TL;DR We usually think of alcohol and sugar as separate, but we’ve also had decades of […]
Antioxidants, Vol. 14, Pages 1490: Antidiabetic Agents as Antioxidant and Anti-Inflammatory Therapies in Neurological and Cardiovascular Diseases
Antioxidants, Vol. 14, Pages 1490: Antidiabetic Agents as Antioxidant and Anti-Inflammatory Therapies in Neurological and Cardiovascular Diseases Antioxidants doi: 10.3390/antiox14121490 Authors: Snehal Raut Luca Cucullo Neurological disorders and cardiovascular disease (CVD) remain leading causes of global morbidity and mortality and often coexist, in part through shared mechanisms of chronic inflammation and oxidative stress. Neuroinflammatory signaling, […]
Oh no, Ozempic! Eli Lilly’s New Weight-Loss Drug KOs Rival Treatments
How do you swear in Danish? Our AI chatbots are much too polite to help us out here, but we suspect you would have heard them all echoing outside the offices of Novo Nordisk yesterday. Eli Lilly, its leading rival in the burgeoning weight-loss drug market, announced trial results for an experimental obesity drug that […]
GLP-1 Drugs Tirzepatide and Semaglutide Provide Protection for Heart Health
submitted by /u/MassGen-Research [link] [comments]
Zealand Pharma, OTR, in $2.5B small-molecule metabolic deal
The quest for metabolic disease assets continues with another player promising top dollar for novel therapeutics that deliver. Copenhagen, Denmark-based Zealand Pharma A/S entered a collaboration and license agreement with newly formed OTR Therapeutics to pursue next-generation small-molecule therapeutics, beyond the Danish firm’s current peptide pipeline candidates focused on the GLP-1, GLP-2, GIP, amylin and […]
GLP-1 Drugs Linked to Lower Epilepsy Risk in Diabetes Patients
(MedPage Today) — GLP-1 receptor agonists were tied to a lower risk of developing epilepsy in adults with type 2 diabetes, a large U.S. study showed. Compared with DPP-4 inhibitors, GLP-1 receptor agonist use was associated with a 16% lower risk…